Form 4 • Statement of Changes in Beneficial Ownership
Type
Sell
Net shares
-2,091
% of shares
-21.16%
Amount (USD)
$61,308
Insider confidence score
22.5 out of 100
Negative
Security
Common Stock
Action
Exercise
Date
2026-03-03
Code
M
Net shares
+6,267.0
Acquired/Disposed
Acquired
Shares Owned Before
3,614.0
Shares Owned After
9,881.0
Security
Common Stock
Action
Tax_withhold
Date
2026-03-03
Code
F
Net shares
-2,091.0
Price per Share
$29.32
Amount (USD)
$61,308.12
Acquired/Disposed
Disposed
Shares Owned Before
9,881.0
Shares Owned After
7,790.0
Security
Stock Option (Right to Buy)
Action
Grant
Date
2026-03-02
Code
A
Net shares
+102,850.0
Acquired/Disposed
Acquired
Shares Owned Before
0.0
Shares Owned After
102,850.0
Security
Restricted Stock Units
Action
Grant
Date
2026-03-02
Code
A
Net shares
+20,550.0
Acquired/Disposed
Acquired
Shares Owned Before
0.0
Shares Owned After
20,550.0
Security
Restricted Stock Units
Action
Exercise
Date
2026-03-03
Code
M
Net shares
-6,267.0
Acquired/Disposed
Disposed
Shares Owned Before
25,068.0
Shares Owned After
18,801.0
1. The option vests and becomes exercisable in 48 equal monthly installments following the date of the grant, subject to the Reporting Person's continued service to Issuer through each vesting date. The date of the grant is March 2, 2026.
2. Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of the Issuer.
3. The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 2, 2026, subject to the Reporting Person's continued service to Issuer through each vesting date.
4. The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 3, 2025, subject to the Reporting Person's continued service to Issuer through each vesting date.
5. Includes 903 shares acquired on March 17, 2025 under Viridian Therapeutics, Inc.'s 2016 Employee Stock Purchase Plan and 1,000 shares acquired on September 17, 2025 under Viridian Therapeutics, Inc.'s 2025 Employee Stock Purchase Plan in transactions that were exempt under Rule 16b-3(c).
This page is for informational purposes only. While we strive for accuracy, the summary may contain inaccuracies or omissions. Please refer to the official SEC filing for authoritative information. Open the SEC filing.